Clinical trial · Observational
Chronotherapy for Radiotherapy of Glioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine if there is any difference in the efficacy of radiotherapy for glioma outcomes in the morning or in the evening. The study team believes that there may be a benefit to taking the radiotherapy at a certain time of day. To test this theory the study asks participants who are already taking radiotherapy for glioma consistently at either the morning or in the evening based on when they currently take their radiotherapy. There will be this study visits where the participant will be asked to fill in questionnaires related to their neurological symptoms, their sleep habits, sleep quality, survival situation, and general health information followed by a blood draw.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| To Determine Whether the Timing of Radiotherapy Has an Effect on Patient Outcomes | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- morning dosing radiotherapy
- interventionNames
- Radiation: radiotherapy
- label
- evening dosing radiotherapy
- interventionNames
- Radiation: radiotherapy
Primary outcomes (1)
- measure
- survival time of glioma patients
- timeFrame
- 1/1/2021-31/12/2021
- description
- Determine whether morning vs. evening dosing radiotherapy could affect the survival time of glioma patients.
Secondary outcomes (1)
- measure
- KPS score of glioma patients.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years; 2. Pathological or cytological diagnosis of glioma; 3. Normal liver and kidney function. Exclusion Criteria: 1. Pregnant or lactating women; 2. Second primary malignancy; 3. Severe lung infection; 4. with high blood pressure although treated with medication; 5. Patients with myocardial ischemia or myocardial infarction, arrhythmia (including QT interval \> 440 ms) or grade II cardiac insufficiency; 6. Arteriovenous thrombosis in 6 months prior to first administration, Such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism; 7. Serious heart, lung and bone marrow impairment; 8. History of severe hypertension or cerebral hemorrhage
References
Publications (0)
Data not yet available